XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

Clinical Evidence in Long Lesions with 48 mm XIENCE™ Stent

The XIENCE Skypoint™ 48 mm Stent is designed so that interventional cardiologists (ICs) can use only one stent in long coronary lesions. Diffuse coronary disease—with long lesions—can otherwise be challenging when employing multiple stents.2

 XIENCE Skypoint 48-mm Stent for long lesions can preclude the need for multiple overlapping stents.

Advantages in Using a Single Long Stent2

There are several advantages in using a single long stent vs several shorter stents in percutaneous coronary intervention (PCI):

  • Reduces procedure time, making PCIs faster and more efficient
  • Reduces radiation and fluoroscopy time
  • Reduces use of contrast

Use of a single longer stent, vs 2 shorter stents, also reduces overlap. In fact, stent overlap has been reported in as many as 30% of patients undergoing PCI. Overlapping stents may also result in:

  • Increased risk of stent fracture3
  • Higher rates of target lesion revascularization (TLR)2

XIENCE Skypoint™ Stent offers a 4.0 x 48 mm stent size to help treat larger vessels where there may be diffuse disease.

Long Coronary Lesions Treated with XIENCE Skypoint 48

XIENCE™ 48 mm Stent Safety Outcomes

Long XIENCE™ Stents continue the tradition of excellent XIENCE™ safety outcomes. XIENCE™ 48 mm Stents demonstrate impressive outcomes in long lesions:

  • 100% device success (mean stented length 58 mm)5
  • 0.1% definite/probable in de novo lesions  >32 mm and <44 mm in length stent thrombosis (ST) at 1 year (mean stented length 39.3 mm)6

Data from XIENCE Prime™ Stent & XIENCE Xpedition™ Stent

In long lesions, XIENCE 48-mm stents achieved 100% device success.
In long lesions, 48-mm stents achieved 0.1% acute definite or probable stent thrombosis.

Long-Term Outcomes in Long, Complex Lesions5

When using XIENCE™ 48 mm Stents in long, complex lesions, there were low rates of myocardial infarction (MI), TLR, and major adverse cardiac events (MACE) 1 year after the index procedure. In this analysis the mean stented length was 58 mm.

When treating long, complex lesions, XIENCE Stent 1-year data showed 0.8% MI, 0.8% TLR, and 3.3% MACE rates.

Consistent Outcomes with Moderate / Long Length Stents7

Additional data supported the safety of XIENCE™ Stent in long lesions, with findings displaying consistent performance between moderate length lesions and long lesions.

 Moderate Length Lesions
(> 24 mm to < 35 mm)
482 Patients
Long Length Lesions
(> 35 mm)
323 Patients
p value
TLF at 1 Year10%8.9%p = 0.63
Mean Lesion Length28.1 mm47.1 mmp < 0.0001

Lower Revascularization in Chronic Total Occlusions (CTO)8

Among the 3-year outcomes of the PRISON-IV trial, the XIENCE™ Stent resulted in significantly lower TLR rates of 4.2% compared to 11.5% with biodegradable polymer sirolimus-eluting stents (BP-SES). The population encompassed patients with complex CTOs.

  • Total stented length with XIENCE™ Stent: 52.3 mm
  • Total stented length with BP-SES: 52.4 mm
When treating CTOs in long lesions, XIENCE Stent has significantly lower target lesion revascularization rate of 4.2% vs 11.5% with BP-SES.

Excellent Long-Term Outcomes at 5 Years9

The 5-year data from the IVUS-XPL study reveal excellent XIENCE™ Stent outcomes in long lesion treatment guided by intravascular ultrasound (IVUS). Study results show low event rates with long lesions treated with long stents.

  • Mean lesion length: 35.1 mm
  • Total stented length: 39.4 mm

Note the low rates of both definite or probable ST (0.3%) and MACE (5.6%).

XIENCE Stent has much lower platelet adhesion compared to Synergy, Orsiro, Ultimaster, Onyx, and BioFreedom drug-eluting stents
Manuals & Technical Resources

Manuals & Technical Resources

Order Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

 XIENCE™ Stent safety outcomes include data on XIENCE Prime™ Stent & XIENCE Xpedition™ Stent.


  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Jurado-Román A, et al. Cardiovasc Revasc Med. 2019;20(8):681-686.
  3. Chinikar M, et al. Current Cardiol Rev. 2014;10:349-354.
  4. Park K, et al. JSCAI. 2023; 10 1001.
  5. Tan CK, et al. Herz. 2019;44:419-424
  6. Hong SFJ, et al. J Am Coll Cardiol Intv. 2016;9:1438-1446.
  7. Bouras G, et al. Catheter Cardiovasc Interv. 2017;89(6):984-991.
  8. Zivelonghi C, et al. JACC Cardiovasc Interv. 2019;12(17):1747-1749. Teeuwen K, et al. JACC Cardiovasc Interv. 2017;10(2):133-143.
  9. Hong SJ, et al. JACC Cardiovasc Interv. 2020;13(1):62-71.

MAT-2312559 v1.0

XIENCE Skypoint™, XIENCE Sierra™, XIENCE Alpine™ (XIENCE™ Family) Everolimus Eluting Coronary Stent Systems



Applies to XIENCE Skypoint™ Stent Systems:

  • Indicated for improving coronary artery luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions ≤ 44 mm in length with reference vessel diameters of ≥ 2.25 mm to ≤ 5.25 mm and for high bleeding risk patients with coronary arteries lesions ≤ 32 mm in length with a reference vessel diameter of ≥ 2.25 mm and ≤ 5.25 mm.
  • Treating de novo chronic total coronary occlusions.

Applies to XIENCE Sierra™ and XIENCE Alpine™ Stent Systems:

  • Indicated for improving coronary artery luminal diameter in patients, including those at high risk for bleeding and those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions (length ≤ 32 mm) with reference vessel diameters of ≥ 2.25 mm to ≤ 4.25 mm.
  • Treating de novo chronic total coronary occlusions.


The XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems are contraindicated for use in:

  • Patients who cannot tolerate, including allergy or hypersensitivity to, procedural anticoagulation or the post-procedural antiplatelet regimen.
  • Patients with hypersensitivity or contraindication to everolimus or structurally-related compounds, or known hypersensitivity to stent components (cobalt, chromium, nickel, tungsten, methacrylic polymer, fluoropolymer), or with contrast hypersensitivity.


  • Each stent and the delivery system are for single use only. Do not reuse, reprocess, or resterilize. Note the product “Use by” date on the package. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device and / or delivery system and / or lead to device failure, which may result in patient injury, illness, or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and / or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device and / or delivery system may lead to injury, illness, or death of the patient.
  • It is not recommended to treat patients having a lesion that prevents complete inflation of an angioplasty balloon.
  • Antiplatelet therapy should be administered post-procedure.
  • This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy.
  • Judicious selection of patients is necessary, since the use of this device carries the associated risk of stent thrombosis, vascular complications, and/or bleeding events.
  • The XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems are coated with an everolimus and polymer coating at the full implant stent length. The distal and intermediate portions of the device, the tip, and tapers of the balloon are coated with HYDROCOAT™ Hydrophilic Coating.

Failure to abide by the warnings in this labeling might result in damage to the device coating, which may necessitate intervention or result in serious adverse events.


  • Implantation of the stent should be performed only by the physicians who have received appropriate training.
  • Stent placement should be performed at centers where emergency coronary artery bypass graft surgery (CABG) can be readily performed.
  • When the XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems are used outside the specified Indications for Use, patient outcomes may differ from the results observed in the SPIRIT family of clinical trials. Compared to use within the specified indications for use, the use of the XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems in patients and lesions outside of the labeled indications, including more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, MI, or death.
  • The extent of the patient’s exposure to drug and polymer is directly related to the number of stents implanted. See Instructions for Use for current data on multiple stent implantation.
  • Safety and effectiveness of the XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems have not been established for subject populations with the following clinical settings:
    • Patients with prior brachytherapy of the target lesion or the use of brachytherapy for treated site restenosis.
    • Conjunctive use of the XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems with either mechanical atherectomy devices or laser angioplasty catheters.
    • Women who are pregnant or lactating, men intending to father children, pediatric.
    • Unresolved vessel thrombus at the lesion site, coronary artery reference vessel diameters < 2.25 mm or > 4.25 mm, for XIENCE Skypoint™ < 2.25 mm or > 5.25 mm, or lesion lengths >44 mm, lesions located in saphenous vein grafts, lesions located in unprotected left main coronary artery, ostial lesions, or lesions located at a bifurcation or previously stented lesions, diffuse disease or poor flow (TIMI < 1) distal to the identified lesions, excessive tortuosity proximal to or within the lesion, recent Acute Myocardial Infarction (AMI) or evidence of thrombus in target vessel, multivessel disease, and in-stent restenosis.
  • Formal drug interaction studies have not been performed with the XIENCE Skypoint™, XIENCE Sierra™ or XIENCE Alpine™ Stent Systems because of limited exposure to everolimus eluted from XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems.
    • Everolimus, the active ingredient in the stents, is an immunosuppressive agent. Consideration should be given to patients taking other immunosuppressive agents or who are at risk for immune suppression.
    • Oral everolimus use in renal transplant and advanced renal cell carcinoma patients was associated with increased serum cholesterol and triglyceride levels, which in some cases required treatment.
    • Nonclinical testing has demonstrated that the XIENCE Sierra™ and XIENCE Alpine™ Stent Systems in single and in overlapped configurations up to 71 mm, for XIENCE Skypoint™ 91 mm in length, are MR Conditional. See Instructions for Use for detailed scanning conditions

Potential Adverse Events

Adverse events that may be associated with PCI treatment procedures and the use of a stent in native coronary arteries include, but are not limited to, the following:

  • Allergic reaction or hypersensitivity to latex, contrast agent anesthesia, device materials, and drug reactions to everolimus, anticoagulation, or antiplatelet drugs
  • Vascular access complications which may require transfusion or vessel repair, including: Catheter site reactions, Bleeding, Arteriovenous fistula; pseudoaneurysm, aneurysm, dissection, perforation/rupture, Embolism, Peripheral nerve injury, Peripheral ischemia
  • Coronary artery complications which may require additional intervention, including: Total occlusion or abrupt closure, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection. Perforation/rupture, Tissue prolapse/plaque shift, Embolism, Coronary or stent thrombosis, Stenosis or restenosis
  • Pericardial complications which may require additional intervention, including: Cardiac tamponade, Pericardial effusion, Pericarditis.
  • Cardiac arrhythmias
  • Cardiac ischemic conditions (including myocardial ischemia, myocardial infarction (including acute), coronary artery spasm, and unstable or stable angina pectoris)
  • Stroke/Cerebrovascular Accident (CVA) and Transient Ischemic Attack (TIA)
  • System organ failures: Cardio-respiratory arrest, Cardiac failure, Cardiopulmonary failure, Renal Insufficiency/failure, Shock
  • Bleeding
  • Blood cell disorders
  • Hypotension and/or hypertension
  • Infection
  • Nausea and vomiting
  • Palpitations
  • Dizziness
  • Syncope
  • Chest Pain
  • Fever
  • Pain
  • Death

The risks described below include the anticipated adverse events relevant for the cardiac population referenced in the contraindications, warnings and precaution sections of the everolimus labels / SmPCs and / or observed at incidences ≥ 10% in clinical trials with oral everolimus for different indications. Please refer to the drug SmPCs and labels for more detailed information and less frequent adverse events.

  • Abdominal pain
  • Anemia
  • Angioedema
  • Arterial Thrombotic Events
  • Bleeding and coagulopathy
  • Constipation
  • Cough
  • Diabetes mellitus
  • Diarrhea
  • Dyspnea
  • Embryo-fetal toxicity
  • Erythema
  • Erythroderma
  • Headache
  • Hepatic artery thrombosis
  • Hepatic disorders
  • Hypersensitivity to everolimus active substance, or to other rapamycin derivates
  • Hypertension
  • Infection (bacterial, fungal, viral or protozoan infections, including infections with opportunistic pathogens). Polyoma virus-associated nephropathy (PVAN), JC virus-associated progressive multiple leukoencephalopathy (PML), fatal infections and sepsis have been reported in patients treated with oral everolimus
  • Kidney arterial and venous thrombosis
  • Laboratory test alterations
  • Lymphoma and skin cancer
  • Male infertility
  • Menstrual irregularities
  • Nausea
  • Nephrotoxicity
  • Non-infectious pneumonitis
  • Oral ulcerations
  • Pain
  • Pancreatitis
  • Pericardial effusion
  • Peripheral edema
  • Pleural effusion
  • Pneumonia
  • Pyrexia
  • Rash
  • Renal Failure
  • Upper respiratory tract infection
  • Urinary tract infection
  • Venous thromboembolism
  • Vomiting
  • Wound healing complications

There may be other potential adverse events that are unforeseen at this time.

MAT-2100879 v7.0